V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015025 | 160007428 | 1.68 | 49.3 | Palliative (P) | 2014-03-27 | 2016-06-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100997946 |
| 160015029 | 160007429 | 1.56 | 110 | Palliative (P) | 2016-11-23 | 2016-11-25 | Trial Unspecified | null | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100620107 |
| 160015030 | 160007430 | 0 | 10 | Palliative (P) | 2020-01-31 | 2020-02-01 | Doxorubicin + Ifosfamide | 02 | N | RITUXIMAB | 100668173 |
| 160015031 | 160007431 | 1.6 | 81.5 | Palliative (P) | 2019-04-04 | 2019-04-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100970960 |
| 160015032 | 160007432 | 1.76 | 83.2 | Curative (C) | 2017-10-13 | 2017-10-30 | Doxorubicin + Ifosfamide | 02 | N | BEP | 100087430 |
| 160015033 | 160007433 | 0 | 79 | Neo-adjuvant (N) | 2017-12-29 | 2017-12-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100012670 |
| 160015034 | 160007434 | 1.56 | 90.3 | null | 2016-06-18 | 2016-06-29 | Carboplatin + Etoposide iv&po | null | N | CARBOPLATIN + PACLITAXEL | 100832361 |
| 160015035 | 160007435 | 1.78 | 70 | Palliative (P) | 2016-09-01 | 2016-09-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101798721 |
| 160015038 | 160007436 | 1.82 | 85.8 | Palliative (P) | 2018-05-19 | 2018-05-23 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100217741 |
| 160015041 | 160007437 | 0 | 60.7 | Palliative (P) | 2016-01-15 | 2016-02-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101404359 |
| 160015043 | 160007438 | 1.72 | 70.8 | null | 2017-03-16 | 2017-03-31 | Doxorubicin + Ifosfamide | 02 | N | IPILIMUMAB + NIVOLUMAB | 100001854 |
| 160015046 | 160007439 | 1.56 | 40.3 | null | 2017-09-28 | 2017-09-29 | ETOP 13-18 BEAT-meso Trial | N | null | DOXORUBICIN | 100746949 |
| 160015048 | 160007440 | 0 | 24.2 | Palliative (P) | 2019-08-31 | 2019-08-31 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101364315 |
| 160015051 | 160007441 | 1.6 | 99.4 | null | 2016-02-19 | 2016-10-18 | Temozolomide 200mg/m2 | 02 | null | ICON9 TRIAL | 100975699 |
| 160015052 | 160007442 | 1.58 | 72.55 | null | 2017-06-05 | 2017-06-07 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100067002 |
| 160015055 | 160007443 | null | null | null | 2019-04-18 | 2019-04-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101120074 |
| 160015057 | 160007444 | 1.73 | 67 | Palliative (P) | 2018-10-03 | 2018-10-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101592374 |
| 160015058 | 160007445 | 1.61 | 68.7 | Palliative (P) | 2019-04-19 | 2019-04-19 | ATOMIC-MESO TRIAL | 99 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101134529 |
| 160015061 | 160007446 | 1.76 | 70.8 | Palliative (P) | 2016-10-02 | 2016-10-15 | Trial Unspecified | 02 | N | DOXORUBICIN | 101744390 |
| 160015062 | 160007447 | 0 | 62.4 | null | 2016-10-13 | 2016-10-23 | DOXORUBICIN | 02 | null | IMATINIB | 100511395 |
| 160015063 | 160007448 | 1.75 | 55.2 | Curative (C) | 2017-09-19 | 2017-09-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101606932 |
| 160015064 | 160007449 | 1.65 | 72 | Curative (C) | 2016-11-30 | 2016-11-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101005566 |
| 160015066 | 160007450 | 1.72 | 61 | null | 2017-01-13 | 2017-01-31 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100197149 |
| 160015067 | 160007451 | 1.88 | 101.5 | Curative (C) | 2017-02-17 | 2017-03-10 | Doxorubicin + Ifosfamide | null | N | ETOP 13-18 BEAT-MESO TRIAL | 100001634 |
| 160015070 | 160007452 | 1.68 | 77 | Palliative (P) | 2017-02-17 | 2017-03-07 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101398682 |
| 160015072 | 160007453 | null | null | null | 2018-06-25 | 2018-07-20 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100361975 |
| 160015073 | 160007454 | 1.69 | 54.5 | Curative (C) | null | 2017-05-11 | Doxorubicin + Olaratumab | N | N | STS RHABDOMYOSARCOMA RMS 2005 VAVV | 101361234 |
| 160015074 | 160007455 | 1.54 | 74.9 | Palliative (P) | 2017-01-27 | 2017-02-22 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100160974 |
| 160015080 | 160007456 | 1.64 | 42.9 | Curative (C) | 2016-10-12 | 2016-10-12 | Cisplatin + Etoposide (3 day) | 01 | N | TRIAL UNSPECIFIED | 100251077 |
| 160015083 | 160007457 | 1.54 | 97.4 | Curative (C) | 2017-02-08 | 2017-02-13 | null | Y | N | DOXORUBICIN + OLARATUMAB | 100392719 |
| 160015085 | 160007458 | 1.75 | 68.2 | Neo-adjuvant (N) | 2018-10-26 | 2018-11-15 | BEP 3 day | 02 | N | VIDE | 101545033 |
| 160015086 | 160007459 | 1.85 | 71 | Palliative (P) | 2018-02-02 | 2018-02-16 | Trial Unspecified | 01 | null | TRIAL UNSPECIFIED | 100564578 |
| 160015087 | 160007460 | 1.74 | 69.3 | Neo-adjuvant (N) | 2018-06-13 | 2018-07-04 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101015503 |
| 160015088 | 160007461 | 1.83 | 85 | Palliative (P) | 2018-06-23 | 2018-07-05 | Liposomal Doxorubicin (Caelyx) | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101421192 |
| 160015089 | 160007462 | 1.8 | 73.6 | Palliative (P) | null | 2018-11-28 | Doxorubicin + Olaratumab | 02 | N | CARBOPLATIN | 101756552 |
| 160015090 | 160007463 | 1.82 | 78 | Curative (C) | 2017-01-27 | 2017-02-10 | Vinorelbine (oral) | 02 | N | EW EUROEWING 2012 ARM B VDC | 100013059 |
| 160015091 | 160007464 | 1.72 | 70 | Palliative (P) | 2016-05-23 | 2016-06-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100361432 |
| 160015092 | 160007465 | 1.72 | 81.9 | Palliative (P) | 2019-03-11 | 2019-03-25 | Pemetrexed | 02 | N | DOXORUBICIN | 100398825 |
| 160015095 | 160007466 | 0 | 16.8 | Palliative (P) | 2018-12-23 | 2018-12-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100379141 |
| 160015096 | 160007467 | 0 | 11.5 | Palliative (P) | 2019-12-19 | 2019-12-31 | CVP R | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100565490 |
| 160015098 | 160007468 | 1.68 | 77.1 | null | 2017-01-05 | 2017-01-08 | ICON8B TRIAL | N | null | LIPOSOMAL DOXORUBICIN | 100797282 |
| 160015099 | 160007469 | 1.31 | 88 | Palliative (P) | 2021-12-16 | 2021-12-16 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100395110 |
| 160015100 | 160007470 | 1.77 | 84 | Palliative (P) | null | 2019-12-31 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101084023 |
| 160015101 | 160007471 | null | 94.3 | Palliative (P) | 2019-08-13 | 2019-08-21 | MELPHALAN | 2 | null | WT SIOP 2002 01 POST OP CARBO, ETOP | 101068082 |
| 160015103 | 160007472 | 1.74 | 97 | Neo-adjuvant (N) | 2017-04-01 | 2017-04-09 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100218320 |
| 160015107 | 160007473 | 1.59 | 59 | null | 2019-05-07 | 2019-05-07 | Trial Unspecified | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101293912 |
| 160015108 | 160007474 | 1.79 | 74.2 | Neo-adjuvant (N) | 2017-01-25 | 2017-01-29 | Liposomal Doxorubicin (Caelyx) | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100751289 |
| 160015109 | 160007475 | 1.64 | 64 | Curative (C) | 2019-07-12 | 2019-08-24 | Carboplatin AUC 2 - 5 | N | null | CARBOPLATIN | 101838683 |
| 160015110 | 160007476 | 1.65 | 67.5 | Palliative (P) | 2017-06-24 | 2017-06-24 | Cisplatin + Pemetrexed | 02 | N | CARBOPLATIN | 101209591 |
| 160015111 | 160007477 | 1.7 | 54.8 | Neo-adjuvant (N) | 2018-12-02 | 2018-12-19 | GC Int Guide Excranial GermCell JEB | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101077102 |